Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880565 · ClinicalTrials.gov registry record · NA
Advanced Reperfusion Strategies for Refractory Cardiac Arrest
A NA study, sponsored by University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03880565: Clinical Trial NA study, sponsored by University of Minnesota.
NCT03880565 is a NA study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880565, a NA study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase II, single center (Under the Center for Resuscitation Medicine at the University of Minnesota Medical School), partially blinded, prospective, intention to treat, safety and efficacy clinical trial, randomizing adult patients (18-75 years old) with refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/VT) out-of hospital cardiac arrest (OHCA) who are transferred by emergency medical services (EMS) with ongoing mechanical cardiopulmonary resuscitation (CPR) or who are resuscitated to receive one of the 2 local standards of care practiced in our community: 1) Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation or 2) Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Primary Outcome
Number of participants who survived to hospital discharge
Interventions
- DEVICE Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation
- DEVICE Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2020-10-09 |
| Phase | NA |
Why NCT03880565 stopped before completion
NCT03880565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation is the first listed.
NCT03880565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03880565 about?
NCT03880565 is a clinical study titled "Advanced Reperfusion Strategies for Refractory Cardiac Arrest". This is a Phase II, single center (Under the Center for Resuscitation Medicine at the University of Minnesota Medical School), partially blinded, prospective, intention to treat, safety and efficacy clinical trial, randomizing adult patients (18-75 years old) with refractory ventricular fibrillation...
What is the current status of trial NCT03880565?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2019-08-09. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT03880565?
The interventions under investigation include: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation (DEVICE), Standard Advanced Cardiac Life Support (ACLS) Resuscitation (DEVICE).
Who is sponsoring clinical trial NCT03880565?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03880565's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI